Open AccessPreventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Author(s) -
PoLan Su,
YiLin Wu,
Wei-Hung Chang,
ChungLiang Ho,
YauLin Tseng,
WuWei Lai,
WuChou Su,
ChienChung Lin,
SzuChun Yang
Publication year - 2018
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/1758835918797589
Subject(s) - medicine , lung cancer , tyrosine kinase , cancer research , brain metastasis , mutation , oncology , tyrosine kinase inhibitor , first line , epidermal growth factor receptor , protein tyrosine kinases , kinase , erlotinib , pathology , cancer , metastasis , gene , receptor , biology , biochemistry , microbiology and biotechnology
Our data suggested that, compared with gefitinib, afatinib provided better benefits significantly in terms of PFS and OS. Both had the same effectiveness in preventing subsequent BM.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom